Radiation Therapy for Follicular Lymphoma

Overseen By May Tsao, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Sunnybrook Health Sciences Centre

Must not be taking: Steroids

Disqualifiers: Systemic therapy, Prognosis < 3 months, Pregnancy

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

27 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine the optimal radiation dose fractionation regimen for low grade follicular lymphoma. It is hypothesized that the complete response rate with the use of 12 Gy in 6 daily fractions is 80% (10% total width of the confidence interval) at 3 months. This phase II study will evaluate whether an intermediate dose for follicular lymphoma is associated with excellent response rates while minimizing acute and late toxicity.

Research Team

May Tsao, MD

Principal Investigator

Sunnybrook Health Sciences Centre

Eligibility Criteria

This trial is for adults over 18 with low-grade (grade 1-2) follicular lymphoma that hasn't been treated with radiation before. It's for those who need radiation for local disease control, have non-bulky targets under 7cm, and can consent to treatment. Pregnant individuals or those on systemic therapy for lymphoma within the last 3 months are excluded.

Inclusion Criteria

My lymphoma is low grade, stages I-IV, and has not been treated with radiation.

I am 18 years old or older.

My cancer targets are smaller than 7cm.

Exclusion Criteria

My doctor expects I have less than 3 months to live.

I am not pregnant.

I haven't had systemic therapy for lymphoma around my radiotherapy time.

Treatment Details

Interventions

• 12 Gy in 6 daily fractions

Trial Overview The study is testing a specific intermediate dose of radiation (12 Gy in 6 daily fractions) to see if it effectively treats follicular lymphoma while reducing both immediate and long-term side effects. The goal is an excellent response rate with minimal toxicity.

Participant Groups

Group I: 12 Gy in 6 daily fractions Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials

693

Recruited

1,569,000+